Clarifying the mechanisms of action of immunotherapeutic drugs and developing a non-invasive radiomics model to predict CD8+ TRM cell dynamics will facilitate the clinical management of HCC. The gene discussed is CD8A; the disease is hepatocellular carcinoma.